Single Photon Emission Computed Tomography of the Normal Human Brain
|ClinicalTrials.gov Identifier: NCT01203891|
Recruitment Status : Completed
First Posted : September 17, 2010
Last Update Posted : September 20, 2010
|Condition or disease|
|Normal Human Subjects|
|Study Type :||Observational|
|Actual Enrollment :||97 participants|
|Official Title:||Single Photon Emission Computed Tomography of the Normal Human Brain|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
Healthy brain subjects
The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
- Baseline SPECT image [ Time Frame: 24 hour assessment and data may be presented up to 10 years later as part of a normative database ]For the baseline resting study with adult subjects approximately 20 milliCuries of Tc-99m-hexamethylpropylene amine oxime (HMPAO, commercially marketed by Amersham Pharmaceuticals under the trade name Ceretec) will be injected after the initial equilibration period. Ceretec is an FDA-approved functional brain imaging radiopharmaceutical currently widely commercially available.
- Concentration SPECT image [ Time Frame: 24 hour assessment and data may be presented up to 10 years later as part of a normative database ]For the concentration study the subject will start the Conner's Continuous Performance Task, a 15-minute computer-administered test of attention, subsequent to the accommodation period. Three minutes into task performance HMPAO will be injected through the catheter with attention to minimal disruption of the subject's attention task. The subject will proceed to completion of the attention task.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01203891
|United States, California|
|Amen Clinics, Inc.|
|Newport Beach, California, United States, 92660|
|Principal Investigator:||Daniel G Amen, MD||Amen Clinics, Inc.|